Found 7 matching trials
NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients NA Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, underdiagn...
Show More Location
University Hospital Düsseldorf
Learn More & Join Trial
Validation of the New Vibration-guided FibroScan Examination NA This is an European, prospective, interventional, multicenter clinical inve...
Show More Learn More & Join Trial
Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference. NA The non-alcoholic fatty liver disease (NAFLD) represents the most common ca...
Show More Location
Queen Elizabeth Hospital Birmingham
Learn More & Join Trial
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference NA Chronic liver diseases (CLDs) represent a major worldwide public health bur...
Show More Location
Centre Hospitalier Universitaire d'Angers
Learn More & Join Trial
Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients NA Non-Alcoholic Fatty Liver is a common clinical and histological condition a...
Show More Location
Hôpital la Pitié Salpêtrière
Learn More & Join Trial
Optimization of Spleen VCTE Examinations with FibroScan NA This is an European, prospective, interventional, and multicenter clinical ...
Show More Location
University Medical Center Rotterdam
Learn More & Join Trial
Development of a FibroScan Liver Examination Using a Single Probe NA This is an exploratory, international, prospective, interventional, multice...
Show More Learn More & Join Trial